RenovoRx's Promising Product Launch and Strategic Expansion Drive Analyst's Buy Rating

RenovoRx's promising product launch and strategic expansion have driven a Buy rating from analyst Swayampakula Ramakanth of H.C. Wainwright. The company's RenovoCath product has shown strong initial sales, and the Phase 3 TIGeR-PAC study is progressing well with positive interim results. Financially, RenovoRx has reported better-than-expected Q2 2025 results, and with sufficient cash reserves, they are well-positioned to fund operations into H1 2026.

RenovoRx, Inc. (Nasdaq: RNXT) reported robust financial results for the second quarter of 2025, marking its second full quarter of revenue generation from RenovoCath sales. The company's CEO, Shaun Bagai, announced that commercial revenue from the RenovoCath device totaled over $400,000, highlighting the strong clinical need and market demand for the patented device. This growth was achieved without a dedicated sales and marketing team, demonstrating the product's initial success and market potential [1].

The company's cash position as of June 30, 2025, stood at $12.3 million in cash and cash equivalents, providing a solid financial foundation for ongoing operations and future growth. RenovoRx's R&D expenses for the quarter were $1.4 million, a decrease of $0.1 million compared to the previous quarter, reflecting the company's efforts to optimize costs [1].

RenovoRx's RenovoCath device has shown promise in the market, with thirteen cancer center customers approved to purchase the device, including several high-volume, National Cancer Institute (NCI)-designated academic and community centers. Four of these centers have used the device in patients, with all making repeat purchase orders subsequently. This momentum underscores the growing clinical demand for novel, localized solid tumor drug-delivery options [1].

The company's Phase III TIGeR-PaC trial, evaluating RenovoCath's use in the treatment of locally advanced pancreatic cancer, is progressing well. The independent Data Monitoring Committee (DMC) recently recommended continuing the trial based on the second pre-planned interim analysis. RenovoRx plans to publish the actual second interim data upon completion of the study, as is common for pivotal Phase III trials [1].

Analyst Swayampakula Ramakanth of H.C. Wainwright has given RenovoRx a Buy rating, citing the company's strong product launch and strategic expansion. Ramakanth's positive outlook is based on RenovoCath's initial sales performance and the progress of the Phase 3 TIGeR-PAC study, which has shown positive interim results [2].

RenovoRx's financial results and market performance have positioned the company well for the first half of 2026. With sufficient cash reserves and a strong pipeline of clinical and commercial initiatives, RenovoRx is poised to continue its growth trajectory in the life sciences sector.

References:
[1] https://www.biospace.com/press-releases/renovorx-reports-commercial-revenue-growth-in-the-second-quarter-2025-and-announces-positive-independent-data-monitoring-committee-recommendation-to-continue-pivotal-phase-iii-tiger-pac-trial-based-on-interim-data-review
[2] https://www.hcwainwright.com/research/renovorx-inc-strong-product-launch-and-strategic-expansion-drive-buy-rating